T he pulmonary route, due to its rich vascularity, large surface area and immunotolerant characteristics, may be an ideal target for drug delivery. Although the inhaled route has been used to deliver drugs used in the management of respiratory disorders, success with peptide delivery has been limited by poor bioavailability. Recent advances in technology have overcome these barriers and have enabled new delivery devices to be developed. Insulin is the first peptide to be delivered successfully by this route and the first of the inhaled insulin delivery devices (Exubera ® ) has now been approved for clinical use. In clinical trials it has been shown to be effective, apparently safe and a preferred alternative to subcutaneously injected meal-time insulin. This new technology offers great convenience to patients needing insulin treatment. While it will considerably reduce the number of injections needed by people with type 1 and type 2 diabetes, it should also encourage more patients to start insulin treatment earlier. The potential benefits from improved adherence and better glycaemic control with this insulin are also significant. 2006;3:179-85 
Introduction
Management of diabetes has traditionally focused on achieving and maintaining tight glycaemic control: indeed, with increasing evidence that good glycaemic control reduces micro-and macro-vascular complications, there is a trend towards tighter targets. [1] [2] [3] [4] In the real world, however, it is difficult to achieve or maintain tight control and only a small percentage of patients actually achieve these targets. 5 Even in those who do achieve target, this is frequently at the expense of hypoglycaemia. These factors, plus the increasing prevalence of diabetes worldwide, have spurred a great interest in the development of new therapies and new ways of delivering evaluated therapies.
Insulin treatment has a unique role in the management of diabetes. It is used to treat both type 1 and type 2 diabetes, is the most potent hypoglycaemic agent, is well tolerated and has an established safety profile. There is also evidence to suggest that patients with type 2 diabetes benefit significantly from early addition of insulin. 6 A major drawback of insulin treatment, however, is that it can be given only as an injection (until now). Patients and health professionals associate injections with pain and inconvenience and this frequently delays insulin initiation or intensification of treatment, ultimately compromising glycaemic control. [7] [8] [9] Availability of insulin treatment through a noninvasive route may overcome some of these barriers and encourage patients to accept insulin therapy more readily. Recent technological advances and better understanding of particle dynamics have inspired the development of several alternative insulin delivery systems. Of these, the pulmonary route appears to be most promising. The first of the inhaled insulin delivery systems (Exubera ® ) has now been approved for clinical use and promises to be a useful alternative to meal-time subcutaneous insulin. In this review we discuss the pharmacological profile, clinical efficacy and safety profile of Exubera ® plus its likely role in the management of diabetes. 
Inhaled route of insulin delivery
Although several approaches to alternative routes of insulin delivery have been explored, only the pulmonary route has so far been successful. 10 The rich blood supply, large surface area, increased permeability and the immunotolerant nature of lung offer a great potential for drug delivery. While initial attempts to deliver insulin via the inhaled route began as early as 1925, it is only in the past decade that significant progress has been made. 11, 12 Several factors, such as particle size, inspiratory volume and breath-holding time, determine the effective delivery of insulin to the alveoli. Particles that are too small (< 1 µm) are exhaled and larger particles (> 5 µm) are deposited in the upper airways. 13 Initial problems related to delivery of large doses of insulin to the alveoli have been overcome by modern inhaler devices. These devices are small and can deliver insulin molecules (between 3 to 5 µm in diameter) that are capable of reaching the lung periphery. In the alveoli, insulin transport occurs by transcytosis and insulin is later released into the blood stream. 14 Several different inhaler devices are currently at different stages of development (see table 1 ). Inhaled human insulin Exubera® is at the most advanced stage among these devices and has been approved for clinical use in Europe and the United States. Exubera ® is a dry powdered formulation of regular human insulin, packed in 1 mg and 3 mg blisters and delivered using a hand-held inhaler device. Each single inhalation of 1 mg and 3 mg blister is equivalent to 3 units and 8 units of subcutaneous insulin, respectively. 15 It is recommended that the device be cleaned regularly and exposure to humidity avoided to ensure dose integrity.
Pharmacological characteristics Pharmacokinetics
The pharmacological properties of inhaled insulin have been investigated in detail in several studies. 16 In pharmacokinetic studies comparing inhaled insulin with regular subcutaneous and rapid-acting analogue insulin, insulin given by the inhaled route was absorbed almost twice as quickly as regular insulin given by the subcutaneous route and as quickly as rapid-acting analogue insulin. Inhaled insulin also had a more prolonged duration of action than analogue insulin, comparable to that of regular subcutaneous insulin.
In a study comparing the time action profiles of inhaled, subcutaneous and intravenous insulin in 11 healthy volunteers, inhaled insulin had a faster onset of action (32 vs. 54 minutes) compared with subcutaneous insulin. 17 The times taken to achieve maximum metabolic effect and maximum insulin concentrations were also faster (108 vs. 147 minutes and 24 vs. 106 minutes, respectively) for inhaled insulin than for subcutaneous insulin.
In a three-way cross-over study involving 17 healthy volunteers comparing Exubera ® inhaled insulin with subcutaneously administered regular human insulin (RHI) and insulin lispro (ILP), inhaled insulin (assessed by glucose infusion rates, GIR) had a faster onset of action (32 vs. 48 and 41 minutes, respectively; p<0.001 for INH vs. RHI and p<0.05 for INH vs. ILP) ( figure 1A ). 18 The duration of action of inhaled insulin was longer than that of insulin lispro and comparable to that of regular subcutaneous insulin (387 vs. 313 and 415 minutes, respectively). The total glucodynamic effect was comparable in all three groups (figure 1B).
Intrasubject variability
In patients with type 1 diabetes, the intra-subject variability for total insulin exposure (AUC) with inhaled insulin was comparable to subcutaneous insulin but the variability in peak insulin concentration (Cmax) was greater for inhaled insulin. 19, 20 In patients with type 2 diabetes no significant differences were noted in intra-subject variability. In a fourway cross-over study, in 20 insulin-naïve patients with type Key: SC = subcutaneous Data from Rave K, Bott S, Heinemann L et al. 18 2 diabetes, a comparison was made of the pharmacokinetic and pharmacodynamic characteristics of inhaled human insulin (Exubera ® ) and subcutaneous insulin. At doses required to produce comparable systemic insulin exposure, the intra-patient variability of Exubera ® was comparable to subcutaneous insulin. 21 
Bioavailability and dose equivalence
In patients with diabetes, bioavailability of inhaled insulin relative to subcutaneous insulin has been estimated to be between 8-11%. 15 Following inhalation of a single dose of inhaled insulin, only 60% of the drug reaches the alveoli. Nearly 30% is deposited in the orpharynx and another 10% is lost in the upper airways. Inhaled insulin is dispensed in 1 mg and 3 mg blisters. Three 1 mg inhalations, however, may cause 40% greater exposure than one 3 mg inhalation. The 1 mg and 3 mg blisters are, therefore, not interchangeable. 15 Efficacy Several studies comparing the efficacy of inhaled insulin with regular subcutaneous insulin have now been published. [22] [23] [24] [25] Most of these studies have been of three months' to six months' duration and have used inhaled insulin or regular subcutaneous insulin in combination with once-or twicedaily long-acting insulins. In almost all these studies the efficacy of inhaled insulin (Exubera ® ) has been shown to be comparable to that of regular subcutaneous insulin. Patients treated with inhaled insulin also had better reductions in fasting and postprandial blood sugars. Although long-term efficacy studies are still ongoing, there is evidence to suggest that this efficacy is maintained in the long term.
In patients with type 2 diabetes who are not on insulin treatment, inhaled insulin has been shown to be more effective than lifestyle interventions or oral agents alone. [26] [27] [28] [29] [30] [31] [32] 
Type 1 diabetes
In a six-month study involving 335 patients with type 1 diabetes, inhaled human insulin (Exubera ® ) was compared with regular insulin given subcutaneously. 23 Patients received meal-time inhaled insulin with bed-time ultralente or two to three injections of their usual insulin regimen. At 24 weeks there was a comparable reduction in HbA 1C in both groups (-0.2 % vs. -0.4 %) (figure 2). A greater reduction in fasting and postprandial glucose and a slightly lower incidence of hypoglycaemia (8.6 vs. 9 events/subject month; risk ratio 0.96 [95% CI 0.93-0.99]) was also observed in patients who received inhaled insulin.
In another study inhaled insulin was compared with regular subcutaneous insulin as a part of a basal bolus regimen. 24 Patients received either preprandial inhaled human insulin (Exubera ® ) or regular insulin along with a basal insulin for 24 weeks. At the end of the study, reductions in HbA 1C were similar in both groups (-0.3 and -0.1%, respectively; adjusted difference -0.16% [CI -0.34 to 0.01]) but patients in the inhaled insulin group showed better reductions in fasting glucose and had fewer hypoglycaemic episodes (9.3 vs. 9.9 ; risk ratio 0.94 [CI 0.91-0.97]).
Type 2 diabetes -insulin-treated
In a six-month study in patients with type 2 diabetes, preprandial inhaled insulin in combination with bed-time ultralente (n=149) was compared with at least twice daily subcutaneous injections of mixed regular/NPH insulin (n=150). 25 At the end of the study, both groups showed similar reductions in HbA 1C (-0.7% and -0.6%, respectively). Patients receiving inhaled insulin had fewer hypoglycaemic events (1.4 vs. 1.6 events/patient month in inhaled insulin and regular groups, respectively). The number of patients achieving target HbA 1C of less than 7% was also higher in the inhaled insulin group (46.9% vs. 31.7%). 
Type 2 diabetes -non insulin-treated
A study involving 145 patients with type 2 diabetes who were failing to achieve optimal control with lifestyle changes randomised patients to receive rosiglitazone or inhaled insulin for three months. 27 Patients who received inhaled insulin had greater reductions in HbA 1C (-2.3% vs. -1.4%) and a significant proportion of them achieved the target HbA 1C (HbA 1C < 8.0% 83% vs. 58%, HbA 1C < 7.0% 44% vs. 18%, and HbA 1C < -6.5% 28% vs. 7.5%).
INH in combination with oral agents
In a multicentre study, patients with type 2 diabetes who were inadequately controlled on oral therapy were randomised to receive inhaled insulin either as monotherapy or in addition to their existing oral therapy (sulphonylurea or repaglinide and metformin or a thiazolidenedione) compared with oral agents alone. 28 The reduction in HbA 1C was greatest in the inhaled insulin plus oral group, followed by the inhaled insulin alone group and the oral agents alone group (-1.9% vs. -1.4% vs. -0.2% for INH + oral, INH alone and oral alone, respectively). A greater proportion of patients receiving inhaled insulin also achieved HbA 1C target of < 7%.
In a recently published 24-week study in patients with poorly controlled type 2 diabetes, addition of inhaled insulin was compared with the addition of another oral agent. Patients inadequately controlled on sulfonylurea monotherapy were randomised to receive either preprandial inhaled insulin or metformin. 29 The reduction in HbA 1C was significantly greater with inhaled insulin than with metformin (-2.06% INH vs. -1.83% metformin; p=0.014) ( figure 3 ). In another similar study, patients with type 2 diabetes inadequately controlled on metformin monotherapy were treated with the addition of glibenclamide or inhaled insulin. 30 Once again, patients treated with inhaled insulin had better reductions in HbA 1C (-2.33% INH vs. -1.88% glibenclamide; p=0.058).
Inhaled insulin in special groups Smokers
The rate and extent of inhaled insulin absorption is significantly increased (up to 3-5 times) in chronic smokers compared to non-smokers. 33, 34 Cessation of smoking appears to have beneficial effects but resumption of smoking may again reverse these effects. 35 'Normalisation' of the absorption, however, may take a long time. 15, 35 The altered pharmacokinetics may affect glycaemic control and increase the risk of hypoglycaemia. Inhaled insulin is, therefore, not recommended in smokers and patients must have quit smoking for at least six months before inhaled insulin can be considered. Passive exposure to smoking, interestingly, has been shown to decrease the bioavailability of inhaled insulin. 36 Asthma/COPD Absorption of inhaled insulin is slower in patients who have mild asthma not treated with a bronchodilator. This may be improved by concomitant use of bronchodilators. 37 In contrast, in patients with chronic obstructive pulmonary disease (COPD), absorption of inhaled insulin (Exubera ® ) is increased two-fold. 15 The exact reasons for this are not well understood.
Other groups
Although no adverse outcomes have been reported with the use of inhaled insulin in pregnancy, given the theoretical risk to the foetus due to the increased antibody response, inhaled insulin is contra-indicated in pregnancy. 15 There is very little experience with inhaled insulin in children and the elderly (aged > 75 years) as most studies have excluded these age groups. These groups are therefore not suitable for inhaled insulin at present. There is no experience of using inhaled insulin in patients with pneumonia. In patients with mild upper respiratory infections, however, no adverse events were noted with use of inhaled insulin. 38 It is advisable to discontinue inhaled insulin temporarily in acutely ill patients.
Safety profile
Hypoglycaemia/weight gain The commonest side effect in patients treated with inhaled insulin was hypoglycaemia. Although the overall rates of mild-to-moderate hypoglycaemia were comparable to those seen in patients treated with subcutaneous insulin, in some studies patients treated with inhaled insulin had more severe hypoglycaemic events. [22] [23] [24] [25] Hypoglycaemic events did decline after continued treatment with inhaled insulin, presumably due to better understanding of the dosing and improved inhaler techniques. 15 number of subjects at baseline; number of subjects at Week 24 n 2 Data from Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M on behalf of the Exubera ® Phase III study group. 29 No significant differences in weight were observed between patients treated with inhaled insulin and subcutaneous insulin. [22] [23] [24] [25] Patients with type 2 diabetes treated with inhaled insulin gained more weight compared to those treated with oral agents alone. 27 Cough Mild-to-moderate cough, occurring within seconds to minutes of inhalation, was reported in up to 20-30% of patients treated with inhaled insulin. Cough was transient, settled with continued treatment and did not result in discontinuation of treatment. [22] [23] [24] [25] [27] [28] [29] [30] 
Effects on pulmonary function and antibody response
The likelihood of lungs being exposed to insulin long term has raised concerns regarding the safety of inhaled insulin. In short-term studies a small (30-40 ml) but consistent decline in FEV 1 (forced expiratory volume in 1 second) was observed in patients treated with inhaled insulin. 15,22-25 Data from extension studies have shown that this decline was most noticeable during the first few weeks of treatment and did not progress with subsequent treatment. 31, 32, [39] [40] [41] Small but clinically insignificant changes in DLCo (carbon monoxide diffusion capacity) were observed in patients treated with inhaled insulin. Again, these changes were non-progressive and were reversed following discontinuation of treatment.
During the screening for clinical studies of Exubera ® , abnormal lung function tests were noted in about one in four patients with diabetes. 15 Although the significance of this is not clear, it is likely some degree of lung function abnormality may be present in people with diabetes. It is therefore recommended that lung function tests are performed before commencing inhaled insulin and every six months thereafter.
High levels of insulin antibodies (at least 5 to 10 times higher) have been noted with inhaled insulin. 15, [23] [24] [25] The rise in antibodies usually occurred in the first 6-12 months of treatment and stabilised subsequently. The antibody response was more pronounced in patients with type 1 diabetes and insulin-treated type 2 diabetes. Young age and female gender are other potential risk factors.
The exact mechanisms that lead to an increased antibody response to inhaled insulin are unknown. Nevertheless, it is reassuring to note that the antibody response is clinically insignificant and is reversible following discontinuation of treatment. In a pooled analysis of the available data on Exubera ® studies, the antibody responses were shown to be not clinically significant. 42 In another study it was shown that the rise in antibody was not associated with any changes in fasting, postprandial or hypoglycaemic events. 43 
Cost of treatment
The annual cost per patient using inhaled insulin, including the cost of the device, is estimated to be approximately £1,100. 44 In addition there will be the costs of education and pulmonary function tests. At the time of writing there are no published studies comparing the cost-effectiveness of inhaled insulin to that of subcutaneously-administered insulin. Economic analyses proposed by the manufacturers of Exubera ® suggest that treatment with inhaled insulin is cost-effective in the long term. 45 The benefits are likely to be due to better adherence to treatment and reduced risk of long-term complications.
Treatment satisfaction and preference Treatment satisfaction, preference and quality of life have been assessed in several studies using standard insulin therapy questionnaires. [46] [47] [48] [49] [50] [51] Several of the efficacy studies have also reported on patient satisfaction. [23] [24] [25] Significantly greater satisfaction with inhaled insulin was reported in all these studies. In a meta-analysis of satisfaction studies, a pooled difference of 24.3 (95% CI 18.14 to 30.44) was observed in favour of inhaled insulin. 44 Patient preference for inhaled insulin also appears to be high, with a greater proportion of patients choosing to continue inhaled insulin and those on subcutaneous insulin opting for inhaled insulin. 47 In another study in patients with type 2 diabetes poorly controlled on lifestyle and oral therapies, inclusion of inhaled insulin in the treatment choices increased patient acceptance of insulin by three times. 52 Quality of life scores have also been high for patients treated with inhaled insulin. 49, 50 
Conclusion
The need for non-invasive insulin delivery has been recognised ever since the discovery of insulin. Non-invasive insulin delivery minimises pain and offers greater convenience to patients who need insulin therapy. This may encourage patients with diabetes to accept insulin therapy more readily and to initiate or intensify insulin treatment. Data from the clinical studies in patients with type 1 and type 2 diabetes suggest that inhaled insulin is an effective and a preferred alternative to subcutaneous insulin. In patients treated with insulin it has comparable efficacy to subcutaneous regular insulin. In patients with type 2 diabetes it has been shown to achieve better reductions in HbA 1C than oral therapies alone. Its fast onset of action and a particularly desirable pharmacokinetic profile should make it ideally suited for prandial glycaemic control. 53 Moreover, it offers the flexibility of adding insulin at any stage of diabetes (with the convenience of oral agents) and may prove to be a valuable addition to existing choices. The improved patient satisfaction and quality of life reported with inhaled insulin may also improve compliance, enabling better glycaemic control to be obtained.
Inhaled insulin is not without limitations, however. For most patients on premixed insulins and on basal bolus regimens, an intermediate-or long-acting insulin injection will still be required. Inhaled insulin is currently contraindicated in patients with asthma, other respiratory disorders, during pregnancy and in children. Similarly, chronic smokers will be excluded unless they quit smoking for at least six months before commencing inhaled insulin. For some patients injectable insulin may still be the best option. The decision to start inhaled insulin must therefore be made after carefully considering the clinical circumstances.
Major concerns regarding the use of inhaled insulin appear to focus on its long-term safety and its costeffectiveness. Although minor differences in lung function have been noted in patients with inhaled insulin, fortunately these have been shown to be non-progressive and clinically insignificant. Similarly, although increased antibody levels have been reported with inhaled insulin, these have not been shown to be clinically significant. A fair degree of caution must, however, be maintained and until long-term data are available lung function must be monitored in all patients receiving inhaled insulin. The demand for inhaled insulin will no doubt place a considerable burden on the healthcare economy. The cost of such treatment will of course need to be balanced against the potential benefits of reduction in long-term complications following better adherence.
Although in an ideal world all patients would be offered the option of non-invasive insulin, practical considerations will limit its use. While there appears to be general agreement about its value in patients with established needle phobia and those with problems related to injection sites, there is considerable scepticism regarding its use in those who are reluctant to accept injections. At a time when lifestyles are becoming increasingly complex, though, it is important to recognise individual needs and to be able to respond to them. Moreover, any therapy that encourages treatment adherence and improves compliance must be regarded as beneficial.
